In the European pharmaceutical industry, there were 14 private equity deals announced in Q3 2024, worth a total value of $1.1bn, according to GlobalData’s Deals Database. The $1.1bn Secondary Buy-Out FairJourney Biologics by Partners Group was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in Europe increased by 642% in Q3 2024 compared with the previous quarter’s total of $148.3m and fell by 13% as compared to Q3 2023. Related deal volume decreased by 13% in Q3 2024 versus the previous quarter and was 30% lower than in Q3 2023.
The top-ranked financial advisors supporting these private equity deals in Europe in 9M 2024 were KPMG International Coop; Rothschild & Co; JPMorgan Chase & Co with 4, 4, 3 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Europe in 9M 2024 were Kirkland & Ellis; Clifford Chance; CMS Legal Services EEIG with 4, 2, 2 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.